SCT 400

Drug Profile

SCT 400

Alternative Names: Recombinant chimeric anti-CD20 monoclonal antibody - Sinocelltech; SCT-400

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sinocelltech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 06 Sep 2017 No development reported - Phase-II for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in China (IV)
  • 18 May 2016 Sinocelltech plans a phase III trial for Diffuse large B cell lymphoma (First-line therapy, Combination therapy) China (NCT02772822)
  • 27 May 2015 Phase-II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (IV) (NCT02456207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top